ASLAN PHARMACEU/ADR (NASDAQ:ASLN) Downgraded by Zacks Investment Research

ASLAN PHARMACEU/ADR (NASDAQ:ASLN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Thursday, reports.

According to Zacks, “ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company’s product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003 both are in clinical stage. ASLAN Pharmaceuticals Limited is based in Singapore. “

A number of other analysts have also recently weighed in on the company. HC Wainwright set a $9.00 price target on ASLAN PHARMACEU/ADR and gave the stock a “buy” rating in a research report on Wednesday, June 5th. ValuEngine raised ASLAN PHARMACEU/ADR from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.

Shares of NASDAQ:ASLN traded down $0.11 on Thursday, reaching $2.62. The company had a trading volume of 100 shares, compared to its average volume of 6,717. ASLAN PHARMACEU/ADR has a twelve month low of $2.51 and a twelve month high of $8.50. The company has a 50-day moving average of $3.18. The stock has a market cap of $86.47 million, a PE ratio of -1.87 and a beta of 2.11.


ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.

Featured Story: Bar Chart

Get a free copy of the Zacks research report on ASLAN PHARMACEU/ADR (ASLN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with's FREE daily email newsletter.